Results 91 to 100 of about 10,879 (228)

Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease

The Korean Journal of Gastroenterology, 2016
Article: Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients with Advanced Liver Disease (Gastroenterology 2015;149:649-659)
Woo Jin Chung
doaj   +1 more source

Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab

Liver International, Volume 45, Issue 10, October 2025.
ABSTRACT Background and Aims Hepatitis C virus (HCV) is a key driver of hepatocellular carcinoma (HCC). However, the impact of HCV eradication on systemic therapy remains unclear. We aimed to assess the safety and efficacy of direct‐acting antivirals (DAA) in patients treated with Atezolizumab plus Bevacizumab (AtezoBev).
Leonardo Stella, Giuseppe Cabibbo, Ciro Celsa, Roberta Ciccia, Alba Sparacino, Fabio Piscaglia, Francesco Tovoli, Andrea Arleo, Bernardo Stefanini, Massimo Iavarone, Roberta D'Ambrosio, Lucia Cerrito, Maria Pallozzi, Francesco Santopaolo, Fabio Marra, Claudia Campani, Chiara Mazzarelli, Raffaella Viganò, Raffaella Tortora, Alessio Aghemo, Stella De Nicola, Tiziana Pressiani, Lorenza Rimassa, Sherrie Bhoori, Salvatore Corallo, Laura Maiocchi, Andrea Martini, Caterina Soldà, Francesco Paolo Russo, Antonio Gasbarrini, Francesca Romana Ponziani   +30 more
wiley   +1 more source

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study

Caspian Journal of Internal Medicine, 2020
Background: Treatment of hepatitis C virus (HCV) infection with recently introduced direct-acting antiviral agents (DAA) is effective and safe, however there is little known regarding safety and efficacy of generic DAAs in the real-life clinical setting.
Heidar Sharafi, Seyed Hoda Alavian, Bita Behnava, Mohammad Saeid Rezaee-Zavareh, Mehri Nikbin, Seyed Moayed Alavian   +5 more
doaj  

Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study

BMC Gastroenterology, 2020
Background We investigated real-world effectiveness and safety of sofosbuvir and the nonstructural protein 5A inhibitors in the treatment of patients infected with hepatitis C virus (HCV) genotypes 1, 2, 3, 4, or 6.
Phunchai Charatcharoenwitthaya, Virasak Wongpaitoon, Piyawat Komolmit, Wattana Sukeepaisarnjaroen, Pisit Tangkijvanich, Teerha Piratvisuth, Theeranun Sanpajit, Chinnavat Sutthivana, Chalermrat Bunchorntavakul, Abhasnee Sobhonslidsuk, Soonthorn Chonprasertsuk, Chotipong Siripipattanamongkol, Supatsri Sethasine, Tawesak Tanwandee, The THASL Collaborating Group for the Study of the Use of Direct-acting Antivirals for Chronic Hepatitis C   +14 more
doaj   +1 more source

Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies [PDF]

, 2018
[Abstract] The presence of resistance‐associated substitutions (RASs) at NS5A region might compromise the efficacy of Direct Acting Antiviral agents (DAAs).
Bagaglio, Black, Calleja, Chen, Dietz, Foster, Kalaghatgi, Lindström, Nelson, Palladino, Paolucci, Pawlotsky, Plaza, Poveda, Poveda, Pérez, Sarrazin, Wyles, Zeuzem, Zeuzem, Zeuzem   +20 more
core   +2 more sources

FIGO guideline on liver disease and pregnancy

International Journal of Gynecology &Obstetrics, Volume 170, Issue 1, Page 28-48, July 2025.
Abstract The number of women entering pregnancy with chronic liver disease is rising. Gestational liver disorders affect 3% of the pregnant population. Both can be associated with significant maternal and fetal morbidity and mortality. European guidance has recently been published to inform management.
Melanie Nana, Virna Medina, Cynthia Maxwell, Ciara McCormick, Gloria Taliani, Ulrich Beuers, Deborah Money, Bo Jacobsson, Anil Kapur, Titus Beyuo, Francisco Ruiloba, Graeme Smith, Lina Bergman, Sharleen O'Reilly, Patrick O'Brien, Mark Hanson, Mary Rosser, Claudio Sosa, Sumaiya Adam, Valerie Guinto, Liona Poon, Fionnuala McAuliffe, Catherine Williamson, on behalf of the FIGO Committee on Impact of Pregnancy on Long‐term Health, FIGO Committee on Infections during Pregnancy and the FIGO Division of Maternal and Newborn Health   +24 more
wiley   +1 more source

Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort [PDF]

, 2016
[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or without ribavirin (RBV) in clinical
Alonso, S., Ampuero, J., Badia, E., Baliellas, C., Buti, M., Carrión, J.A., Castro-Iglesias, Ángeles, Devesa, M.J., Esteban, R., Fernández, I., Fernández-Carrillo, C., Fernández-Rodríguez, C.M., Gea, F., Granados, R., Gómez, A., Lens, S., Llerena, S., Montero, J.L., Olveira, A., Pascasio, J.M., Planas, J.M.M., Polo, B., Real, Y., Rincón, D., Riveiro-Barciela, M., Rubín, A., Salmerón, J., Turnes, J.   +27 more
core   +2 more sources

Clearance of Hepatitis C Viremia During Direct‐Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism

Alimentary Pharmacology &Therapeutics, Volume 62, Issue 2, Page 146-158, July 2025.
HCV clearance during direct‐acting antiviral therapy rapidly increases serum lipids and lipoproteins, potentially elevating cardiovascular risk. These metabolic changes, mediated by genes regulating hepatic lipogenesis, suggest that lipid levels should be closely monitored post‐SVR to assess long‐term cardiovascular implications.
Zahra Sarrafan‐Chaharsoughi, Varun Takyar, Sungyoung Auh, Gavin Nee, Ahmad Alawad, Brent S. Abel, Devika Kapuria, Colleen Byrnes, Anna Wolska, David E. Kleiner, Robert Shamburek, Alan T. Remaley, Marc G. Ghany   +12 more
wiley   +1 more source

Acute Kidney Injury in Patients Undergoing Chronic Hepatitis C Virus Treatment With Ledipasvir/Sofosbuvir

Hepatology Communications, 2018
Ledipasvir‐sofosbuvir, a once‐a‐day, oral combination pill, was approved in 2014 for the treatment of chronic hepatitis C infection. Initial trials did not comment on nephrotoxicity; however, recent data suggest a risk of acute kidney injury (AKI) with ...
Patrick R. Brown, Omar Sadiq, Alexander Weick, Adrienne Lenhart, Mohammad Elbatta, Christopher Fernandez, Anas Kutait, Robert Pompa, Syed‐Mohammed Jafri   +8 more
doaj   +1 more source

Drug-induced lung disease adverse effect with Ledipasvir Acetonate/Sofosbuvir

Journal of Pharmaceutical Health Care and Sciences, 2020
Background Interferon and ribavirin have been used as therapeutic agents for chronic hepatitis C infection or C-compensated cirrhosis in the conventional treatment.
Sachiko Omotani, Toshihiko Ishizaka, Miki Inoue, Koji Nishida, Yukako Yasui, Yasutoshi Hatsuda, Junji Mukai, Michiaki Myotoku   +7 more
doaj   +1 more source